Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1998;31:1338-1342

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, S.
Right arrow Articles by Gardner, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, S.
Right arrow Articles by Gardner, D. G.

(Hypertension. 1998;31:1338-1342.)
© 1998 American Heart Association, Inc.


Scientific Contributions

Suppression of ANP Gene Transcription by Liganded Vitamin D Receptor

Involvement of Specific Receptor Domains

Songcang Chen; Jianming Wu; Jui-Cheng Hsieh; G. Kerr Whitfield; Peter W. Jurutka; Mark R. Haussler; ; David G. Gardner

From the Metabolic Research Unit, University of California at San Francisco (S.C., J.W., D.G.G.); and the Department of Biochemistry, The University of Arizona, Tucson (J.-C.H., G.K.W., P.W.J., M.R.H.).

Correspondence to David G. Gardner, MD, Box 0540, Metabolic Research Unit, University of California at San Francisco, San Francisco, CA 94143.

Abstract—We showed previously that liganded vitamin D receptor (VDR) effects a suppression of human atrial natriuretic peptide (hANP) gene-promoter activity in cultured neonatal rat atrial myocytes. In the present study, we have attempted to identify the structural domains of the VDR that are involved in mediating this suppression. We examined the effects of a series of VDR mutants on a cotransfected hANP promoter-driven chloramphenicol acetyltransferase (CAT) reporter. Neither the native VDR nor any of the mutants tested displayed inhibitory activity in the absence of the 1,25-dihydroxyvitamin D3 (VD3) ligand. {Delta}134, a deletant harboring solely the DNA binding region of the VDR, and L254G, a mutant shown to be defective in retinoid X receptor (RXR) heterodimer formation in other systems, were as effective as the native VDR in reducing promoter activity. HBD, a deletant containing only the hormone-binding domain of the VDR, and K246G, a point mutant that is defective in the activation function of the receptor, did not attenuate reporter activity. A similar activity profile was displayed when a positively regulated promoter containing a direct-repeat vitamin D responsive element (DR3-CAT) was examined in these cells. Liganded VDR, the {Delta}134 mutant, and liganded L254G effected increases in DR3-CAT activity of 2.5-, 2-, and 4-fold, respectively. Two nonhypercalcemic analogues of VD3 (RO 23–7553 and RO 25–6760) displayed the same inhibitory activity as VD3. These studies suggest that the inhibition of hANP promoter activity requires both the DNA binding and activation functions of the receptor but does not appear to require formation of a classic RXR{alpha}-VDR heterodimer.


Key Words: peptides • transcription, genetic • vitamin D3 • vitamin D receptor mutants




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
A. L. Negri
Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD
Nephrol. Dial. Transplant., February 1, 2009; 24(2): 341 - 344.
[Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. B. Pai and T. A. Conner
Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D
Journal of Pharmacy Practice, June 1, 2008; 21(3): 214 - 224.
[Abstract] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
W. Xiang, J. Kong, S. Chen, L.-P. Cao, G. Qiao, W. Zheng, W. Liu, X. Li, D. G. Gardner, and Y. C. Li
Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems
Am J Physiol Endocrinol Metab, January 1, 2005; 288(1): E125 - E132.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Chen, J. Cui, K. Nakamura, R. C. J. Ribeiro, B. L. West, and D. G. Gardner
Coactivator-Vitamin D Receptor Interactions Mediate Inhibition of the Atrial Natriuretic Peptide Promoter
J. Biol. Chem., May 12, 2000; 275(20): 15039 - 15048.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
D. ZEHNDER, R. BLAND, E. A. WALKER, A. R. BRADWELL, A. J. HOWIE, M. HEWISON, and P. M. STEWART
Expression of 25-Hydroxyvitamin D3-1{alpha}-Hydroxylase in the Human Kidney
J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2465 - 2473.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
S. Chen, C. H. R. M. Costa, K. Nakamura, R. C. J. Ribeiro, and D. G. Gardner
Vitamin D-dependent Suppression of Human Atrial Natriuretic Peptide Gene Promoter Activity Requires Heterodimer Assembly
J. Biol. Chem., April 16, 1999; 274(16): 11260 - 11266.
[Abstract] [Full Text] [PDF]